Actelion receives FDA complete response letter for Zavesca

Tuesday 9 March 2010

Actelion Ltd said that it has received a complete response letter from the US Food and Drug Administration for its treatment for Niemann-Pick disease, Zavesca (miglustat). This means the agency cannot approve the application in its present form.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

See map: Google Maps